SCHEMBL21045124

SCHEMBL21045124

Cc1cc(C(=O)NCCCc2ccc(-c3ccccc3F)cc2)n(C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
MAPKAPK2 P49137 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29411543 1.00 MAPT (0.47) MAPTHDAC3HDAC4HDAC1HDAC2
SCHEMBL21045139 0.90 LIPG (0.45) MAPTHDAC3HDAC4HDAC1HDAC2
SCHEMBL29411603 0.90 LIPG (0.45) MAPTHDAC3HDAC4HDAC1HDAC2
SCHEMBL21045081 0.88 HDAC6 (0.47) MAPTHDAC6SMN1; SMN2MEN1ALDH1A1
SCHEMBL29411430 0.88 HDAC6 (0.47) MAPTHDAC6SMN1; SMN2MEN1ALDH1A1
SCHEMBL21045157 0.88 HDAC3 (0.56) MAPTHDAC3HDAC4HDAC1HDAC2
SCHEMBL29411416 0.88 HDAC3 (0.56) MAPTHDAC3HDAC4HDAC1HDAC2
SCHEMBL21045463 0.88 GRIA4 (0.44) MAPTHDAC3HDAC4HDAC1HDAC2
SCHEMBL29411625 0.88 GRIA4 (0.44) MAPTHDAC3HDAC4HDAC1HDAC2
SCHEMBL21045279 0.87 CTSL (0.47) MAPTHDAC3HDAC4HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
WO-2019113242-A1 TUBULIN INHIBITORS Lin BioScience, LLC (US) 2019-06-13 WO disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089539-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB MAPT 24/4885HDAC3 291/4885HDAC4 263/4885
US-11040945-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB MAPT 24/4885HDAC3 291/4885HDAC4 263/4885
US-20190169127-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB MAPT 24/4885HDAC3 291/4885HDAC4 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.